Quantcast
Last updated on April 18, 2014 at 14:48 EDT

Latest Biogen Idec Stories

2013-05-30 12:27:17

However, Aubagio's Prescriber Base Continues to Lag Behind That of Novartis's Gilenya at Same Stage of Product Launch, According to a New Report from BioTrends Research Group EXTON, Pa., May 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of surveyed neurologists have prescribed Aubagio, the second oral disease-modifying agent (DMA) marketed for multiple sclerosis...

2013-05-29 16:25:41

Elan's proposed transactions offer no coherent strategy and are not in the best interests of Elan or its shareholders NEW YORK, May 29, 2013 /PRNewswire/ -- Royalty Pharma announces its recommendation that the shareholders of Elan Corporation, plc (NYSE: ELN) vote "NO" on each of the four proposals offered by Elan at its upcoming extraordinary general meeting on June 17, 2013. Royalty Pharma will also be soliciting proxies from the shareholders of Elan to vote against each of the...

2013-05-28 08:27:57

Underscores Compelling Logic for Elan Stockholders to SELL their shares to Royalty Pharma NEW YORK, May 28, 2013 /PRNewswire/ -- Royalty Pharma announces today that it has issued an investor presentation related to Royalty Pharma's increased offer to acquire Elan Corporation, plc (NYSE: ELN) for $12.50 per share in cash. The presentation outlines why Royalty Pharma believes Elan Stockholders should accept its compelling, fully-financed and cash confirmed offer, which is not...

2013-05-24 08:22:43

NEW YORK, May 24, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels its original offer for Elan Corporation (NYSE: ELN). Background On 2 May 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") made an offer for the entire of the issued and to be issued share capital of Elan Corporation, plc ("Elan") (the...

2013-05-23 08:27:14

June 19-20, 2013 New York Academy of Sciences, New York, NY ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec). JC polyomavirus (JCV) is the causative agent of Progressive Multifocal...

2013-05-23 08:26:45

NEW YORK, May 23, 2013 /PRNewswire/ -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that it has committed to waive down the Acceptance Threshold from 90 percent to 50 percent of Maximum Elan Shares Affected plus one Elan Share in accordance with the terms of the Revised Offer Document issued today, subject to the conditions summarized below. Under the terms of the Increased Offer, Royalty Pharma is offering to acquire Elan (NYSE: ELN) for $12.50 per share in cash. The...

2013-05-16 23:20:51

Summit features an expanded roster of meetings with increased formulation foci plus new meetings delving into early IND strategies and biomanufacturing. Needham, Mass. (PRWEB) May 16, 2013 Cambridge Healthtech Institute will host its fifth annual The Bioprocessing Summit from August 19-23, 2013 at the Renaissance Waterfront Hotel in Boston, MA. The ten meetings comprising the Summit provide a close-up look at the current strategies and innovations for optimizing bioprocesses while...

2013-05-13 20:22:14

NEW YORK, May 13, 2013 /PRNewswire/ -- Cadwalader, Wickersham & Taft LLP, a leading counselor to global financial institutions and corporations, announced today that client Elan Corporation, plc, a biotechnology company headquartered in Ireland, will purchase from Theravance, Inc. a 21% participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc: RELVAR(TM) ELLIPTA(TM)/BREO(TM) ELLIPTA(TM), AORO(TM)...

2013-05-06 08:26:20

CARDIFF, Calif., May 6, 2013 /PRNewswire/ -- NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's. "The current therapeutic options for PD are limited in scope and duration of utility. Motoric symptoms can be attenuated, but over time, there is a price to be paid, as L-dopa related dyskinesias eventually emerge for many patients,"...

2013-05-02 08:36:57

Offer Price Reflects $1 Billion Dutch AuctionStrikePrice of $11.25 per Elan Share NEW YORK, May 2, 2013 /PRNewswire/ -- Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued an offer document dated 2 May 2013 (the "Offer Document"). In the Offer Document, Royalty Pharma confirms the Offer Price set forth in its Rule 2.5 Announcement of 15 April (please see the Offer Document for details). The Offer Price reflects Elan's (NYSE: ELN) $1 billion Dutch Auction share...